Claim OwnershipBioTech IQ
Subscribed: 25Played: 469
Subscribe
© 2024 BioTech IQ
Description
Increase your IQ and understanding of the Biotech industry by listening to interviews with key business leaders who have built successful companies and departments. We discuss everything from the science, clinical operations, clinical development, safety/PV and more! We address how each function plays an important role in the drug approval process. We also discuss the people that make up these departments. Get ready to hear about cutting edge development and the people who make it happen!
69 Episodes
Reverse
On this episode of BioTech IQ, Ammon interviews Paul Lammers the CEO of Triumvira about developing autologus cell therapies using their T-Cell Antigen Coupler Platform (TAC). During this insightful discussion Paul talks about how he started in the industry, running a biotech company in today's environment, and what sets Triumvira's T-Cell therapy apart from the rest! Don't miss it!Show support for show https://www.buymeacoffee.com/biotechiqCheck out the books recommended by Paul:CEO Excellence - https://amzn.to/3OGjI3GThe Emperor of All Maladies - https://amzn.to/3IDyZ1lSupport the showCheck me out on LinkedIn https://www.linkedin.com/in/ammonr/
Bryan Kobel decided to pursue a career in biotech after seeing its massive opportunities to change the world. He sits down with Ammon Rivera to share how he translated his background as an investment banker into his role as the CEO of TC BioPharm, a company that develops cancer therapy. He opens up about finding his purpose in this space that allows him to save lives and molds him into a compassionate leader. Bryan also talks about their allogenic Gamma Delta T Cell therapy platform, which involves injecting isolated Gamma Delta T Cells to treat cancer-stricken patients. He explains how they are continuously evolving this method to make it cost-effective and easily accessible to underserved and economically disadvantaged individuals.Support the show! https://www.buymeacoffee.com/biotechiqSupport the showCheck me out on LinkedIn https://www.linkedin.com/in/ammonr/
In this episode of BioTech IQ Ammon shares some real stats on the state of the hiring market in Biotech/pharma. We discuss what both job seekers and hiring managers can do to increase their success when searching/hiring. Bringing innovative treatments that make a difference in the life of people is the goal but the business side of drug development is as complex as the science sometimes. Don't miss it!Leave a review and share! Thanks!Support the show here: https://www.buymeacoffee.com/biotechiqhttps://thebiotechiqpodcast.com/Support the showCheck me out on LinkedIn https://www.linkedin.com/in/ammonr/
Cary Claiborne Sr. is the CEO of Adial Pharmaceuticals and member of the board. He also sits on the board for Nuerosense Therapeutics and CytRx. Cary holds an MBA from Villanova University. In this episode Cary shares how his interest in finance at an early age led him to become the CFO of a small biotech that led him to where he is today.Support the show: https://www.buymeacoffee.com/biotechiqBooks that Cary referenced:Holy Bible - https://amzn.to/3Y6um4WControl Your Destiny or Someone Else Will - https://amzn.to/3ITDuWcSupport the showCheck me out on LinkedIn https://www.linkedin.com/in/ammonr/
On this episode of BioTech IQ Ammon interviews Farahnaz Forozan, PhD, MB who is a 20 year veteran in the industry. She discussed how she immigrated from Iran to the United States, became a Phd, was the Head of Translational Development with BMS, to running her own consulting practice. She has taken all this experience and is driving innovation within biotech.Don't miss it! It's about Innovation.www.forozanoncogenconsulting.comSupport the show here: https://www.buymeacoffee.com/biotechiqhttps://thebiotechiqpodcast.com/Support the showCheck me out on LinkedIn https://www.linkedin.com/in/ammonr/
Throughout many of the discussions on BioTech IQ it is clear that a combination of therapies is likely the answer to treating cancers and other diseases. This is a point well made by the guests on this episode of the show. CEO Jack Hoppin, PhD and Chief Scientific Officer, John Babich PhD are Co-Founders of Ratio Therapeutics. Both bring a successful background in biotech and not only discuss what their organization is doing but lessons they have learned as entrepreneurs in treatment development. Don't miss it!Support the show here: https://www.buymeacoffee.com/biotechiqhttps://thebiotechiqpodcast.comDon't forget to check out the YouTube Channel! https://www.youtube.com/@biotechiqpodcast4943Support the showCheck me out on LinkedIn https://www.linkedin.com/in/ammonr/
Science will only get you so far in biotech. No matter how ingenious your products are, you will never succeed as a company if you don’t have all the pieces if business development in place. And there is no greater piece than the people piece. As the Chief People Officer of Biomea Fusion, Naomi Cretcher knows that company culture is what is going to make or break her company’s success. Despite everything that went on with COVID and with a recession looming, Naomi is confident that investing on their talent pool with pay off in terms of company success. She joins Ammon Rivera in this episode to tell us what it takes exactly to build an excellent company culture in a biotech company and why the act of building one will give any business its biggest ROI. Tune in!Support the show: https://www.buymeacoffee.com/biotechiqSupport the showCheck me out on LinkedIn https://www.linkedin.com/in/ammonr/
Ammon shares an update what has changed and why no new episodes have been release for the last couple of months. And discussing some interesting facts about the biotech industry and where it's headed from a hiring perspective.Atlas 2022 Year in Reviewhttps://youtu.be/LONM9ekseJ4Support the showCheck me out on LinkedIn https://www.linkedin.com/in/ammonr/
In this epsisode of BioTech IQ Ammon interviews the Chief Growth Officer of M2GEN Todd Johnson, MD. M2GEN partners with 18 of the nation’s leading cancer centers, through the Oncology Research Information Exchange Network® (ORIEN), to deliver oncology informatics-based solutions to accelerate therapy discovery, development and delivery of precision medicine. M2GEN is one of the only companies to ensure that patient data has been granted through consent.M2GEN utilizes the IRB-approved protocol, Total Cancer Care®, that allows for enhanced patient engagement through the ability to re-contact patients and facilitates linkages across disparate sources of data, creating a research ecosystem which can significantly benefit patients and improve patient care. Listen to more interviews at thebiotechiqpodcast.comDan Sfera's interview with Ammon https://youtu.be/86MtcfBnUmgSupport the showCheck me out on LinkedIn https://www.linkedin.com/in/ammonr/
There isn’t a cure for cancer yet, but if everyone can come together, we may find that cure sooner rather than later. One biotech company that is trying to solve cancer is Qualigen Therapeutics. With their oncology therapeutics pipeline, they could be onto something with their leading asset QN-302. Join Ammon Rivera as he talks to the Chief Medical Officer of Qualigen Therapeutics, Tariq Arshad, MD, about where they are right now in their therapeutics pipeline. Learn why cancer is the greatest injustice and how Tariq is fighting to stop it. Find out more about their research in Qualigen Therapeutics when it comes to killing these cancer cells. Let's all come together and stop cancer.Support the showCheck me out on LinkedIn https://www.linkedin.com/in/ammonr/
In this episode of BioTech IQ, Ammon Rivera continues his exploration of Qualigen Therapeutics by interviewing the founder and CEO of the company Michael Porier. Michael discusses how Qualigen was started and the motivation behind the therapeutics pipeline. There are incredible developments underway for the company, and the turn of the market is hopefully on its way as well. Listen in on their discussion about the growth of Qualigen and what investors can look forward to as they continually develop drugs with a goal of turning cancer into a manageable disease instead of life-threatening one. Hear all about it and more of the company’s significant moves in the market by tuning in to this episode.Support the showCheck me out on LinkedIn https://www.linkedin.com/in/ammonr/
Qualigen Therapeutics is a biotechnology company that develops novel therapeutic products to treat adult and pediatric patients with rare cancers. A leading name in the industry, they have decided to build a therapeutics pipeline within the last few years. In this first episode of a three-part series featuring top executives of Qualigen Therapeutics, Ammon interviews Amy Broidrick, the firm's President and Chief Strategy Officer. She shares what she brings to the table in the company's transition from a preclinical stage company to a brand new business venture. She also talks about her deep love for market research, her career's pivotal and most fulfilling moments, and how she deals with negativity.Support the showCheck me out on LinkedIn https://www.linkedin.com/in/ammonr/
AI has gone so far as to potentially change drug development, and these developments have the potential to make a difference in people’s lives. On this episode of BioTech IQ, Ammon interviews Noam Solomon, the CEO of Immunai. Immunai is developing an AI platform that leverages big data, single cell multiomics, and machine learning to bridge the gap between casual immunology and translational disease biology. Their platform is mapping the human immune system at an unprecedented level of granularity, allowing them to identify the right targets to go after. In this interview, Noam shares his knowledge on reprogramming the immune system for better diagnosis and treatment. He shares his amazing team and how they make patient’s lives easier and meaningful. Tune in to learn more about immunotherapies!Support the showCheck me out on LinkedIn https://www.linkedin.com/in/ammonr/
Social anxiety disorder is the third most common mental health disorder. Over 23 million Americans alone are affected by it. This disorder can continue to grow into depression and drug abuse, so it's very important to catch it early so it can be stopped. But how can it be stopped? Shawn Singh, the CEO and Director of VistaGen Therapeutics, and his team are creating a nasal spray to help people with social anxiety disorder. Just like an inhaler for asthma, this nasal spray can do for social anxiety. Join Ammon Rivera as he talks to Shawn Singh about the PH94B nasal spray. Find out how it works and how far along they are in the process. If they get approved, VistaGen has the opportunity to be the first FDA-approved acute treatment for adults with social anxiety disorder. Discover how VistaGen is going beyond the current standard of care for anxiety, depression, and CNS disorders. Support the showCheck me out on LinkedIn https://www.linkedin.com/in/ammonr/
Companies in the biotech space are making contributions to help find a cure for cancer. Today’s guest is no exception. In today’s episode, Ammon Rivera sits down with Daniel Teper, Co-Founder and CEO of Cytovia Therapeutics, to talk about the unique technology they’re using to develop a treatment for cancer. Daniel discusses how they’ve developed three types of iPSC-Derived Natural Killer Cells and are now targeting unmet needs in treating hepatocellular carcinoma (HCC). There is a lot of disruptive innovation coming from the biotech industry. Daniel also discusses how the field is dealing with worsening market conditions amidst recent news of a special purpose acquisition with Isleworth Healthcare Corporation. There’s much to learn from this episode, both in medicine and economics.Support the showCheck me out on LinkedIn https://www.linkedin.com/in/ammonr/
On this episode of BioTech IQ Ammon talks with Co-Founder and CEO of Anima Biotech, Yochi Slonim. Yochi is a serial entrepreneur with experience building multiple successful companies before starting Co-Founding Anima. Anima Biotech is developing mRNA Lighting, a novel platform for the discovery of selective small molecule mRNA drugs and their mechanisms of action. Automated high scale phenotypic screening combining live biology with AI mRNA image analysis for the discovery of small molecule mRNA drugs and their mechanisms of action.https://www.animabiotech.com/Catch the latest on BioTech IQhttps://thebiotechiqpodcast.com/ Support the showCheck me out on LinkedIn https://www.linkedin.com/in/ammonr/
Cell cycle biology is key to understanding cancer. You have to hit the cancer cells early before they become smart and adapt. There is a stage in the cell cycle called mitosis. This is where, if done right, can cause cancer cells to suicide. This is where the biotech company, Cyclacel comes in with all their research into the cell cycle of cancer. Join Ammon Rivera as he talks to Spiro Rombotis about some of Cyclacel's cell cycle therapies. Spiro is the CEO of Cyclacel. His mission is to use cell cycle biology to treat cancer and other serious diseases. Ammon and Spiro go over the use of Cyclin-dependent Kinase and its role in the cell cycle. Spiro also talks about Cyclacel's pipeline and drug candidates. They also go through discussion strategy, the drug approval process, and what it means to fail fast.Support the showCheck me out on LinkedIn https://www.linkedin.com/in/ammonr/
Have you ever thought about having replacement parts for your body? It sounds like science fiction, but it’s now as real as the eyes you’re using to read this, thanks to cell-based therapy. Brian Culley is one of the leaders in this field. He is the CEO of Lineage Cell Therapeutics, a company developing treatments for multiple indications based on their proprietary cell-based therapy platform. Leveraging in-house manufacturing, they are attacking multiple indications from ophthalmology to immuno-oncology. In this episode, Brian joins Ammon Rivera to explain what their strategy is, where they are currently in the development process, and where they’re going from there.Support the showCheck me out on LinkedIn https://www.linkedin.com/in/ammonr/
The biotech industry has been bombarded with disruptions in recent years, from a global pandemic to rising global tensions. How are they dealing with the supply chain issues and how else has it impacted the industry? In this episode, Ammon Rivera sits down with two-peat guest, Guillermo Morales, PhD, CEO of Innoventyx. Guillermo makes us privy to the issues brought on by COVID-19 and the geopolitical tensions such as the Russia-Ukraine conflict. He also discusses intellectual property in greater depth and why it’s important to act fast when patenting your product. Moving from Latin America to the United States, Guillermo also shares his experience learning and re-learning the science in both languages and how it impacts communication. Don’t miss out on their enlightening conversation by tuning in!Support the showCheck me out on LinkedIn https://www.linkedin.com/in/ammonr/
In this episode of BioTech IQ host Ammon Rivera talks about the current state of the market with respect to recruiting. He also shares a real and recent experience highlighting the challenges of compensation and it role in landing the right individual for the job. https://thebiotechiqpodcast.com/https://www.linkedin.com/in/ammonr/Support the showCheck me out on LinkedIn https://www.linkedin.com/in/ammonr/
Comments
Download from Google Play
Download from App Store
United States